| Bioactivity | Ublituximab (LFB-R603; TG-1101; TGTX-1101) is a next-generation, type 1 chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen. Ublituximab has anticancer effects[1]. |
| Invitro | Ublituximab 经过糖工程改造，具有含低岩藻糖的可结晶片段 (Fc) 区域，可增强抗体依赖性细胞毒性[1]。 |
| Name | Ublituximab |
| CAS | 1174014-05-1 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Matthew Lunning, et al. Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2019 Nov 21;134(21):1811-1820. |